Clinical Trial: A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer

U.S., Jan. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07323576) titled 'A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer' on Jan. 06.

Brief Summary: This is a blinded Phase 2 study designed to evaluate the safety and efficacy of inavolisib with bevacizumab and chemotherapy, in participants with metastatic colorectal cancer (mCRC) whose tumors have a PIK3CA mutation. The study has a safety run-in period followed by a randomized period.

Study Start Date: Feb. 01

Study Type: INTERVENTIONAL

Condition: Colorectal Cancer

Intervention: DRUG: Inavolisib

Participants...